DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3 mg/kg+methotrexate (MTX)) at weeks 0, 2, 6 and every 8 weeks thereafter. At week 22, 474 patients were still in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van den Bosch, Filip, Veys, Eric M, Mielants, Herman, De Clerck, Luc, Peretz, Anne, Malaise, Michel, Verbruggen, Leon, Vastesaeger, Nathan, Geldhof, Anja, Boullart, Luc, De Keyser, Filip
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2005
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1257436/
https://ncbi.nlm.nih.gov/pubmed/16207323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar1787
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak